natgillin/translations-raw huggingface dataset:
Following an application from the Association de la Transformation Laitière Française (ATLA) submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of vitamin D on bone growth (Question No EFSA-Q-2008-323) [5].
Družba Association de la Transformation Laitière Française (ATLA) je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi vitamina D na rast kosti (vprašanje št. EFSA-Q-2008-323) [5].
The claim proposed by the applicant was worded as follows: ‘Vitamin D is essential for the bone growth of children’.
Vlagatelj je predlagal naslednjo trditev: „Vitamin D je bistven za rast kosti pri otrocih.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship was established between the intake of vitamin D and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da je vzročno-posledična povezava med uživanjem vitamina D in navedeno trditvijo bila utemeljena.
Following an application from Yoplait Dairy Crest Ltd submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of calcium and vitamin D on bone strength (Question No EFSA-Q-2008-116) [6].
Družba Yoplait Dairy Crest Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi kalcija in vitamina D na krepitev kosti (vprašanje št. EFSA-Q-2008-116) [6].
The claim proposed by the applicant was worded as follows: ‘Calcium and vitamin D, as part of a healthy diet and lifestyle, build stronger bones in children and adolescents’.
Vlagatelj je predlagal naslednjo trditev: „Kalcij in vitamin D, kot dela zdrave prehrane in zdravega življenjskega sloga, krepita kosti otrok in mladostnikov.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship was established between the intake of calcium and vitamin D and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da je vzročno-posledična povezava med uživanjem kalcija in vitamina D in navedeno trditvijo bila utemeljena.
A health claim reflecting this conclusion should be considered as complying with the requirements set out in Regulation (EC) No 1924/2006, and it should be included in the Community list of permitted claims.
Trditev ob spremembi besedila je treba šteti za skladno z zahtevami iz Uredbe (ES) št. 1924/2006 in jo je treba vključiti na seznam dovoljenih trditev v Skupnosti.
Following an application from the Association de la Transformation Laitière Française (ATLA) submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of calcium on bone growth (Question No EFSA-Q-2008-322) [7].
Družba Association de la Transformation Laitière Française (ATLA) je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi kalcija na rast kosti (vprašanje št. EFSA-Q-2008-322) [7].
The claim proposed by the applicant was worded as follows: ‘Calcium is needed for the healthy bone growth of children’.
Vlagatelj je predlagal naslednjo trditev: „Kalcij je potreben za rast zdravih kosti otrok.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship was established between the intake of calcium and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da je vzročno-posledična povezava med uživanjem kalcija in navedeno trditvijo bila utemeljena.
Following an application from the Association de la Transformation Laitière Française (ATLA) submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of proteins of animal origin on bone growth (Question No EFSA-Q-2008-326) [8].
Družba Association de la Transformation Laitière Française (ATLA) je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi beljakovin živalskega izvora na rast kosti (vprašanje št. EFSA-Q-2008-326) [8].
The claim proposed by the applicant was worded as follows: ‘Proteins of animal origin contribute to children’s bone growth’.
Vlagatelj je predlagal naslednjo trditev: „Beljakovine živalskega izvora pomagajo pri rasti kosti otrok.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship was established between the intake of total protein and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da je vzročno-posledična povezava med uživanjem skupnih beljakovin in navedeno trditvijo bila utemeljena.
Article 16(4) of Regulation (EC) No 1924/2006 provides that an opinion in favour of authorising a health claim should include certain particulars.
Člen 16(4) Uredbe (ES) št. 1924/2006 določa, da kadar mnenje podpira odobritev zdravstvene trditve, mora vključevati nekatere podatke.
Accordingly, those particulars should be set out in the Annex I to the present Regulation as regards the seven authorised claims and include, as the case may be, the revised wording of the claim, specific conditions of use of the claim, and, where applicable, conditions or restrictions of use of the food and/or an additional statement or warning, in accordance with the rules laid down in Regulation (EC) No 1924/2006 and in line with the opinions of the Authority.
Zato je treba za sedem odobrenih trditev v Prilogi I k tej uredbi določiti navedene podatke in za vsak primer posebej v skladu s pravili iz Uredbe (ES) št. 1924/2006 in mnenji Agencije opredeliti spremembo besedila trditve, posebne pogoje, pod katerimi se trditev uporablja, ter po potrebi pogoje ali omejitve uporabe živila in/ali dodatno pojasnilo ali opozorilo.
One of the objectives of Regulation (EC) No 1924/2006 is to ensure that health claims are truthful, clear and reliable and useful to the consumer, and that wording and presentation have to be taken into account in that respect; therefore where the wording of claims has the same meaning for consumers as that of an authorised health claim as they demonstrate the same relationship that exists between a food category, a food or one of its constituents and health, included in Annex I they should be subject to the same conditions of use indicated therein.
Eden od ciljev Uredbe (ES) št. 1924/2006 je zagotoviti, da je zdravstvena trditev resnična, jasna, zanesljiva in za potrošnika uporabna ter da se pri tem upoštevata besedilo in predstavitev trditve; kadar ima besedilo trditve za potrošnike enak pomen kot dovoljena zdravstvena trditev iz Priloge I, če predstavljata isto povezavo med kategorijo živila, živilom ali njegovo sestavino in zdravjem, je treba to trditev uporabljati pod istimi pogoji, ki so navedeni v navedeni prilogi.
Following an application from BIO SERAE submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of NeOpuntia® on blood lipid parameters associated with cardiovascular risks, especially HDL-cholesterol (Question No EFSA-Q-2008-214) [9].
Družba BIO SERAE je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi NeOpuntia® na vrednosti lipidov v krvi, povezanih s kardiovaskularnim tveganjem, zlasti na vrednost HDL-holesterola (vprašanje št. EFSA-Q-2008-214) [9].
The claim proposed by the applicant was worded as follows: ‘NeOpuntia® helps to improve blood lipid parameters associated with cardiovascular risks, especially the HDL-cholesterol’.
Vlagatelj je predlagal naslednjo trditev: „NeOpuntia® pomaga izboljšati raven lipidov v krvi, povezanih s kardiovaskularnim tveganjem, zlasti HDL-holesterola.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship could not be established between the consumption of NeOpuntia® and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem NeOpuntia® in navedeno trditvijo ni bila utemeljena.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne sme odobriti.
Following an application from Valio Ltd submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lactobacillus helveticus fermented Evolus® low-fat milk products on arterial stiffness (Question No EFSA-Q-2008-218) [10].
Družba Valio Ltd. je v skladu s členom 14(1)(a) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi mlečnih izdelkov z manj maščobe Evolus®, fermentiranih z Lactobacillus helveticus, na togost arterij (vprašanje št. EFSA-Q-2008-218) [10].
The claim proposed by the applicant was worded as follows: ‘Evolus® reduces arterial stiffness’.
Vlagatelj je predlagal naslednjo trditev: „Evolus® zmanjša togost arterij.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of Lactobacillus helveticus fermented Evolus® low-fat milk products and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem mlečnih izdelkov z manj maščobe Evolus®, fermentiranih z Lactobacillus helveticus, in navedeno trditvijo ni bila utemeljena.
Following an application from Martek Biosciences Corporation submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of docosahexaenoic acid (DHA) and arachidonic acid (ARA) on neural development of the brain and eyes (Question No EFSA-Q-2008-120) [11].
Družba Martek Biosciences Corporation je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o vplivih dokosaheksenojske kisline (DHA) in arahidonske kisline (ARA) na razvoj živčevja v možganih in očeh (vprašanje št. EFSA-Q-2008-120) [11].
The claim proposed by the applicant was worded as follows: ‘DHA and ARA support neural development of the brain and eyes’.
Vlagatelj je predlagal naslednjo trditev: „DHA in ARA podpirata razvoj živčevja v možganih in očeh.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of the food/constituent (DHA and ARA) starting at six months of age and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem živil/sestavin (DHA in ARA) od šestega meseca starosti in navedeno trditvijo ni bila utemeljena.
In addition, the Authority concluded that the consumption of baby foods/formula supplemented with DHA and ARA from six months to one year of age might have a beneficial effect on visual acuity maturation in infants breast-fed until the age of 4-6 months.
Poleg tega je Agencija sklenila, da uživanje otroške hrane/otroških formul z dodanima DHA in ARA od šestega meseca do enega leta starosti lahko ugodno vpliva na dozorevanje ostrine vida pri otrocih, dojenih z materinim mlekom do četrtega ali šestega meseca.
The Authority concluded also that no evidence had been presented on the effects of DHA and ARA supplementation starting at six months of age on visual maturation in healthy infants that had not been breastfed but fed unenriched formula during the first months of life.
Agencija je tudi sklenila, da niso bili predloženi dokazi o vplivih uživanja DHA in ARA od šestega meseca starosti na razvoj ostrine vida pri zdravih otrocih, ki v prvih mesecih življenja niso bili dojeni z materinim mlekom, temveč z neobogatenimi formulami.
A health claim reflecting this conclusion could not comply with the general principles and requirements of Regulation (EC) No 1924/2006, and especially Articles 3, 5 and 6, and should not be authorised.
Zdravstvena trditev, ki odraža ta sklep, ne more izpolnjevati splošnih načel in zahtev iz Uredbe (ES) št. 1924/2006 ter zlasti členov 3, 5 in 6, in se ne sme odobriti.
Following an application from the National Dairy Council submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of dairy foods (milk and cheese) on dental health (Question No EFSA-Q-2008-112) [12].
Družba National Dairy Council je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi mleka in mlečnih izdelkov (mleka in sira) na zdravje zob (vprašanje št. EFSA-Q-2008-112) [12].
The claim proposed by the applicant was worded as follows: ‘Dairy foods (milk & cheese) promote dental health in children’.
Vlagatelj je predlagal naslednjo trditev: „Mleko in mlečni izdelki (mleko in sir) krepijo zdravje zob otrok.“
On the basis of the data presented, the Authority concluded that the food category dairy foods (milk and cheese) subject of the health claim has not been sufficiently characterised, and a cause and effect relationship had not been established between the consumption of milk or cheese and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da kategorija živil mleko in mlečni izdelki (mleko in sir), na katero se nanaša zdravstvena trditev, ni bila ustrezno opredeljena ter da vzročno-posledična povezava med uživanjem mleka ali sira in navedeno trditvijo ni bila utemeljena.
Following an application from the National Dairy Council submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of dairy foods on healthy body weight (Question No EFSA-Q-2008-110) [13].
Družba National Dairy Council je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi mleka in mlečnih izdelkov na zdravo telesno težo (vprašanje št. EFSA-Q-2008-110) [13].
The claim proposed by the applicant was worded as follows: ‘Three portions of dairy food everyday, as part of a balanced diet, may help promote a healthy body weight during childhood and adolescence’.
Vlagatelj je predlagal naslednjo trditev: „Trije obroki mleka in mlečnih izdelkov dnevno kot del uravnotežene prehrane lahko pomagajo pri vzdrževanju zdrave telesne teže v otroštvu in mladostništvu.“
On the basis of the data presented, the Authority concluded that the food category dairy foods (milk and cheese) subject of the health claim has not been sufficiently characterised and that a cause and effect relationship had not been established between the daily consumption of dairy foods (milk, cheese and yogurt) and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da kategorija živil mleko in mlečni izdelki (mleko in sir), na katero se nanaša zdravstvena trditev, ni bila ustrezno opredeljena ter da vzročno-posledična povezava med uživanjem mleka in mlečnih izdelkov (mleka, sira in jogurta) in navedeno trditvijo ni bila utemeljena.
Following an application from enzyme.pro.ag, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of regulat®.pro.kid IMMUN on the immune system of children during growth (Question No EFSA-Q-2008-082) [14].
Družba enzyme.pro.ag je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi regulat®.pro.kid IMMUN na imunski sistem otrok v obdobju rasti (vprašanje št. EFSA-Q-2008-082) [14].
The claim proposed by the applicant was worded as follows: ‘regulat®.pro.kid IMMUN supports, stimulates and modulates the immune system of children during growth’.
Vlagatelj je predlagal naslednjo trditev: „regulat®.pro.kid IMMUN podpira, spodbuja in krepi imunski sistem otrok v obdobju rasti.“
On the basis of the data presented, the Authority concluded that the food for which the claim is made, ‘regulat®.pro.kid IMMUN’, has not been sufficiently characterised, and that a cause and effect relationship had not been established between the consumption of regulat®.pro.kid IMMUN and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da živilo regulat®.pro.kid IMMUN, na katero se nanaša zdravstvena trditev, ni bilo ustrezno opredeljeno ter da vzročno-posledična povezava med uživanjem regulat®.pro.kid IMMUN in navedeno trditvijo ni bila utemeljena.
Following an application from enzyme.pro.ag, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of regulat®.pro.kid BRAIN on the mental and cognitive development of children (Question No EFSA-Q-2008-083) [15].
Družba enzyme.pro.ag je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi regulat®.pro.kid BRAIN na duševni in kognitivni razvoj otrok (vprašanje št. EFSA-Q-2008-083) [15].
The claim proposed by the applicant was worded as follows: ‘regulat®.pro.kid BRAIN contributes to mental and cognitive development of children’.
Vlagatelj je predlagal naslednjo trditev: „regulat®.pro.kid BRAIN pomaga pri duševnem in kognitivnem razvoju otrok.“
On the basis of the data presented, the Authority concluded that the food for which the claim is made ‘regulat®.pro.kid BRAIN’, has not been sufficiently characterised, and that a cause and effect relationship had not been established between the consumption of regulat®.pro.kid BRAIN and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da živilo regulat®.pro.kid BRAIN, na katero se nanaša zdravstvena trditev, ni bilo ustrezno opredeljeno ter da vzročno-posledična povezava med uživanjem regulat®.pro.kid BRAIN in navedeno trditvijo ni bila utemeljena.
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the calming effect of I omega kids®/Pufan 3 kids® (Question No EFSA-Q-2008-091 and – Question No EFSA-Q-2008-096) [16].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi s pomirjujočim učinkom I omega kids®/Pufan 3 kids® (vprašanje št. EFSA-Q-2008-091 in vprašanje št. EFSA-Q-2008-096) [16].
The claim proposed by the applicant was worded as follows: ‘calming’.
Vlagatelj je predlagal naslednjo trditev: „Pomirja.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of DHA and eicosapentaenoic acid (EPA) and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem DHA in eikosapentenojske kisline (EPA) ter navedeno trditvijo ni bila utemeljena.
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on serenity (Question No EFSA-Q-2008-092 and Question No EFSA-Q-2008-097) [17].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi I omega kids®/Pufan 3 kids® na umirjenost (vprašanje št. EFSA-Q-2008-092 in vprašanje št. EFSA-Q-2008-097) [17].
The claim proposed by the applicant was worded as follows: ‘provide serenity and room for a beneficial development of the child’.
Vlagatelj je predlagal naslednjo trditev: „Zagotavlja umirjenost in zmožnost za razvoj otroka.“
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of DHA and EPA and the claimed effect.
Agencija je na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem DHA in EPA ter navedeno trditvijo ni bila utemeljena.
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on vision (Question No EFSA-Q-2008-095 and Question No EFSA-Q-2008-100) [18].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi I omega kids®/Pufan 3 kids® na vid (vprašanje št. EFSA-Q-2008-095 in vprašanje št. EFSA-Q-2008-100) [18].
The claim proposed by the applicant was worded as follows: ‘help to support vision’.
Vlagatelj je predlagal naslednjo trditev: „Pomaga pri razvoju vida“.
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on mental development (Question No EFSA-Q-2008-098 and Question No EFSA-Q-2008-104) [19].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi I omega kids®/Pufan 3 kids® na duševni razvoj (vprašanje št. EFSA-Q-2008-098 in vprašanje št. EFSA-Q-2008-104) [19].
The claim proposed by the applicant was worded as follows: ‘help to support mental development’.
Vlagatelj je predlagal naslednjo trditev: „Pomaga pri duševnem razvoju.“
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related the effects of I omega kids®/Pufan 3 kids® on concentration (Question No EFSA-Q-2008-094 and Question No EFSA-Q-2008-099) [20].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi I omega kids®/Pufan 3 kids® na zbranost (vprašanje št. EFSA-Q-2008-094 in vprašanje št. EFSA-Q-2008-099) [20].
The claim proposed by the applicant was worded as follows: ‘help to promote concentration’.
Vlagatelj je predlagal naslednjo trditev: „Pomaga pri izboljšanju zbranosti.“
Following two applications from Pharma Consulting & Industries submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of I omega kids®/Pufan 3 kids® on thinking capacity (Question No EFSA-Q-2008-093 and Question No EFSA-Q-2008-101) [21].
Družba Pharma Consulting & Industries je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogi, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi I omega kids®/Pufan 3 kids® na miselne zmožnosti (vprašanje št. EFSA-Q-2008-093 in vprašanje št. EFSA-Q-2008-101) [21].
The claim proposed by the applicant was worded as follows: ‘helps to promote the thinking capacity’.
Vlagatelj je predlagal naslednjo trditev: „Pomaga pri povečanju miselne zmožnosti.“